Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD.
Neurology
; 61(2): 206-11, 2003 Jul 22.
Article
em En
| MEDLINE
| ID: mdl-12874400
ABSTRACT
BACKGROUND:
The neurodegenerative process in Alzheimer's disease (AD) and in the Lewy body variant of AD (LBV) patients is characterized by cholinergic dysfunction and deposition of amyloid beta-peptide (Abeta) 1-40 and 1-42; however, the differential effects of Abeta species on the cholinergic system are not completely clear.OBJECTIVE:
To better understand the relationship between levels of Abeta1-40 and 1-42 on cholinergic deficits in AD and LBV patients.METHODS:
Levels of choline acetyltransferase (ChAT) activity and ChAT immunoreactivity in the plaques in the frontal cortex of patients with AD and LBV were correlated with Abeta1-42 and 1-40 levels determined by ELISA and with neuropathologic and neurologic markers.RESULTS:
Although the overall levels of ChAT activity were reduced in AD and LBV cases, there was a direct correlation with Abeta1-42 levels. Furthermore, patients with high Abeta1-42 levels had more abundant cholinergic dystrophic neurites in the plaques than cases with lower Abeta1-42.CONCLUSION:
Abeta1-42 may also trigger cholinergic dysfunction by promoting aberrant neuritic sprouting.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Fibras Colinérgicas
/
Peptídeos beta-Amiloides
/
Doença por Corpos de Lewy
/
Doença de Alzheimer
/
Lobo Frontal
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Neurology
Ano de publicação:
2003
Tipo de documento:
Article